Johnson & Johnson’s Q1 earnings call reveals encouraging pharmaceutical sales growth and sequentical improvements across segments despite challenges in the OTC business and healthcare sector. The stock is likely to experience a moderate positive impact in the short term, propelled by strong pharmaceuticals performance and positive currency impact, partially offset by continued pressures in the medical devices segment and the OTC business.riel دوران embrace باید اینجا میِ technically ([1])

1